Biocytogen and Whitehawk partner to develop ADCs
Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.